Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Jul 07, 2026, 09:30 ET Akston's NGF-Targeting Ambifect® Candidates Demonstrate Clinically Meaningful Osteoarthritis Pain and Function Improvements Comparable to Bedinvetmab in Head-to-Head Canine Study
Medicine (ACVIM) Forum showed that AKS-548d and AKS-734 induced sustained anti-NGF antibody responses, functional neutralization of NGF binding to TrkA, clinically meaningful reductions in canine osteoarthritis pain, and improvements in function, with a well-tolerated safety profile.In
More news about: Akston Biosciences
Jun 05, 2026, 09:00 ET VetrixBio Announces Positive Clinical Data for VTX-304, a First-in-Class Bispecific Antibody for Canine Osteoarthritis
bedinvetmab, as measured by the modified Canine Brief Pain Inventory (mCBPI).In biochemical and cell-based studies, VTX-304 demonstrated potent NGF/TrkA pathway inhibition and effective blockade of ADAMTS-5-mediated aggrecan cleavage, consistent with cartilage protection.Osteoarthritis affects
More news about: VetrixBio, Inc.